DEVELOPMENT SAFETY UPDATE REPORT PSIKET 22.7.2022 – 21.7.2023

DEMLOVÁ, Regina and Michaela KUBELOVÁ. DEVELOPMENT SAFETY UPDATE REPORT PSIKET 22.7.2022 – 21.7.2023. NA. Brno: MU LF/MŠMT/NÚDZ, 2023, 14 pp. NA.

Basic information

• Original name: DEVELOPMENT SAFETY UPDATE REPORT PSIKET 22.7.2022 – 21.7.2023
• Name in Czech: DEVELOPMENT SAFETY UPDATE REPORT PSIKET 22.7.2022 – 21.7.2023
• Name (in English): DEVELOPMENT SAFETY UPDATE REPORT PSIKET 22.7.2022 – 21.7.2023
• Authors: DEMLOVÁ, Regina (203 Czech Republic, guarantor) and Michaela KUBELOVÁ (203 Czech Republic, belonging to the institution).
• Edition: NA. Brno, 14 pp. NA, 2023.
• Publisher: MU LF/MŠMT/NÚDZ

Other information

• Original language: Czech
• Type of outcome: Research report
• Field of Study: 30230 Other clinical medicine subjects
• Country of publisher: Czech Republic
• Confidentiality degree: is not subject to a state or trade secret
• WWW: PSIKET
• RIV identification code: RIV/00216224:14110/23:00131970
• Organization unit: Faculty of Medicine
• Keywords (in Czech): Klinická studie; CZECRIN; Psilocybin; deprese komorbidní; ONKOLOGICKÉ ONEMOCNĚNÍ
• Keywords in English: Clinical study; CZECRIN; Psilocybin; comorbid depression; ONCOLOGICAL DISEASE
• Tags: interim report, MU, NÚDZ

Abstract

Psilocybin - a strategy of rapid antidepressant response in depression comorbid with cancer, a randomized double-blind study with the possibility of entering open extension. Klinické hodnocení PSIKET_002CZE je zaměřeno na studium antidepresivního účinku přírodního alkaloidu psilocybinu u populace pacientů s depresivní poruchou, která doprovází onkologické onemocnění (komorbidní deprese). Účinek je srovnáván s kontrolními látkami s akutním krátkodobým antidepresivním působením (s ketaminem) a bez antidepresivního působení (s midazolamem).

Abstract (in English)

Psilocybin - a strategy of rapid antidepressant response in depression comorbid with cancer, a randomized double-blind study with the possibility of entering an open extension. Clinical trial PSIKET_002CZE is focused on the study of the antidepressant effect of the natural alkaloid psilocybin in a population of patients with a depressive disorder that accompanies an oncological disease (comorbid depression). The effect is compared with control substances with acute short-term antidepressant action (with ketamine) and without antidepressant action (with midazolam).

Links

• 90249, large research infrastructures: Name: CZECRIN IV